Loading…
Based on limited metadata, the FDA issued a Warning Letter to Aspire Pharmaceuticals, Inc. on November 22, 2022, regarding dietary supplements. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The letter falls under FDA's dietary supplement regulatory authority, though the specific issuing office and violation details remain unknown. This summary should be supplemented with the complete Warning Letter for comprehensive compliance analysis.